252 related articles for article (PubMed ID: 32041837)
1. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
[TBL] [Abstract][Full Text] [Related]
3. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
5. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
[TBL] [Abstract][Full Text] [Related]
7. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
Kuang R; Jahangiri A; Mascharak S; Nguyen A; Chandra A; Flanigan PM; Yagnik G; Wagner JR; De Lay M; Carrera D; Castro BA; Hayes J; Sidorov M; Garcia JLI; Eriksson P; Ronen S; Phillips J; Molinaro A; Koliwad S; Aghi MK
JCI Insight; 2017 Jan; 2(2):e88815. PubMed ID: 28138554
[TBL] [Abstract][Full Text] [Related]
8. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
Carbonell WS; DeLay M; Jahangiri A; Park CC; Aghi MK
Cancer Res; 2013 May; 73(10):3145-54. PubMed ID: 23644530
[TBL] [Abstract][Full Text] [Related]
9. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
[TBL] [Abstract][Full Text] [Related]
12. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
13. Raddeanin A inhibited epithelial-mesenchymal transition (EMT) and angiogenesis in glioblastoma by downregulating β-catenin expression.
Wu B; Zhu J; Dai X; Ye L; Wang B; Cheng H; Wang W
Int J Med Sci; 2021; 18(7):1609-1617. PubMed ID: 33746577
[TBL] [Abstract][Full Text] [Related]
14. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
15. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
[TBL] [Abstract][Full Text] [Related]
16. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
Xu H; Rahimpour S; Nesvick CL; Zhang X; Ma J; Zhang M; Zhang G; Wang L; Yang C; Hong CS; Germanwala AV; Elder JB; Ray-Chaudhury A; Yao Y; Gilbert MR; Lonser RR; Heiss JD; Brady RO; Mao Y; Qin J; Zhuang Z
Oncotarget; 2015 May; 6(14):11882-93. PubMed ID: 25957416
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis.
Joseph JV; Conroy S; Pavlov K; Sontakke P; Tomar T; Eggens-Meijer E; Balasubramaniyan V; Wagemakers M; den Dunnen WF; Kruyt FA
Cancer Lett; 2015 Apr; 359(1):107-16. PubMed ID: 25592037
[TBL] [Abstract][Full Text] [Related]
18. Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib.
Nurwidya F; Takahashi F; Winardi W; Tajima K; Mitsuishi Y; Murakami A; Kobayashi I; Nara T; Hashimoto M; Kato M; Hidayat M; Suina K; Hayakawa D; Asao T; Ko R; Shukuya T; Yae T; Shimada N; Yoshioka Y; Sasaki S; Takahashi K
Thorac Cancer; 2021 May; 12(10):1536-1548. PubMed ID: 33764690
[TBL] [Abstract][Full Text] [Related]
19. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.
Otani Y; Ichikawa T; Kurozumi K; Inoue S; Ishida J; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Date I
Oncogene; 2018 Feb; 37(6):777-786. PubMed ID: 29059154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
